Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They are seasonal biotech stock players:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=95077463
My sincere congratulations to the shorts! I will have Johnnie Walker Blue Label at dinner.
Let the shorts dance on the ceiling in hell!
It's not for me. It only works for you. Were you there dancing on the ceiling? Nice job!
P.S. lax etc are part of this takedown which is why he lashed out at grandma.
Will the criminals involved in the takedown go to hell and bring the ceiling dancers with them?
It is interesting that certain old-timer Ariad believers, who used to claim they knew what they owned, have shorted what they knew due to the taken-down.
Certain old-timer Ariad longs have jointed class action lawsuits against Ariad, hoping to get $0.001 shares per 1000 qualified shares. LOL! It's normal, too. Anyway, money is money.
-------------
True longs and only the Ariad true longs will be greatly rewarded. Ariad will be the next BIIB and the next Amgen despite the painful set back.
All my posts are factual. Each of them is good enough to make bloria_research dance on the ceiling. Thank you!
One who cheers about pre-market dawn must be long on the stock. Do you agree?
Fundamentally, Ariad is as strong as ever in spite of the painful set back induced by the FDA that has exaggerated the SAEs of Iclusig and withdrawn the lifesaving drug so that doctors fear their patients are going to die and so that the cancer patients panic.
ARIA will be the next BIIB and the next AMGN.
Evidence Supports AP26113 in Patients with Non–Small Cell Lung Cancer With Brain Metastases, by Alice Goodman, The ASCO Post, December 1, 2013, Volume 4, Issue 19
Tapered dose steroids were used to resolve symptoms over 1 week, and patients restarted the drug at 90 mg/d without further pulmonary symptoms, he said. Future studies will employ a step-up approach, initiating the drug at 90 mg/d for 7 days before moving up to 180 mg/d.
AP26113 was generally well tolerated. Common adverse events of all grades were nausea (38%), fatigue (34%), and diarrhea (32%); 12% had elevated liver enzymes. Treatment-emergent grade 3 or higher adverse events were reported in 2% to 4% across all dose levels, and included dyspnea, fatigue, diarrhea, hypoxia, and pneumonitis. Pulmonary events, which occurred early in 3/25 patients at the 180-mg/d level and seemed to be rarer at lower doses, were responsive to drug interruption, although resolution, despite continued dosing, was also reported. Future studies will employ a step-up approach, initiating the drug at 90 mg/d for 7 days before moving up to 180 mg/d.
AP26113 had robust antitumor activity in crizotinib-resistant and crizotinib-naive NSCLC patients, including those with brain metastasis after crizotinib treatment.
“Most if not all patients with NSCLC will become resistant to crizotinib, and half of those who are resistant have brain metastasis,” explained lead author D. Ross Camidge, MD, PhD, Associate Professor and Director of the Thoracic Oncology Clinical Program at University of Colorado, Denver.
Shorts must be scared like a hell, I truly love this. We might even gap up tomorrow, oh well it is our time "again"!
Enjoying a fantastic bottle, just for today's victory wink.
42M shares changed hands and these buyers are not "average joe"s.
I expect this is a false breakout, and would sell puts into close. I can't now myself. There will be no news this soon from the EMA or FDA.
Oh, what a feeling, I'd be dancing on the ceiling in hell.
One should not put any of his money in the stock market if he could not afford to lose it.
Unlike some of the so-called Ariad longs, I did not cry about the taken-down flash crash.
I will vote him for the greatest CEO of all time if Harvey Berger's legal team acts against the FDA.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94997236
I thought I was obligated to answer your questions politely.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94998974
Haven't you started our conversation and then replied my posts with "???" and "????"?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94990415
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94992739
I was just answering your ??? + ???? = 7 questions.
--------------
How is the magic phrase patently silly you suggested to the ceiling dancer working for him? Are you terminally stupid?
Any news will be good news because Ariad has run out of shoes to drop has gotten the worst news thanks to the FDA. Don't you think so? You don't have to count on it. However, counting on it or not counting on it is at your own risk. You will see what is going to happen.
What happened to Ariad during 10/1999 - 03/2000 will probably be repeated. By 03/2014, ARIA may reach $50+ if history repeats. History repeats itself, doesn't it. Who knows?
I am not a trader. I don't predict target price because I don't think it is predictable. If anybody interprets my statement above that way, it is his/her freedom. However, he/she should have noticed the word "probably" in my statement. Ariad's history tells that during the period of 10/1999 - 03/2000, ARIA rose more than 50 folds. Who predicted when ARIA dropped below $1.00? History may or may not repeat itself. Who knows? When ARIA was at $25.40 in Oct, 2013, who predicted it would drop to $2.15 a year later? You were bullish back a year. you would have said $2.15 was off reality. However, it turned out that the reality was that people had to face the reality.
ARIA may reach $50. If it does happen, the shorts will have to face the reality. One usually doesn't realize reality until he/she faces it.
Buy and hold the gold bags of ARIA shares. You won't regret if you are a long term investor.
If I hadn't done a double check, I would have thought I wandered onto the Yahoo message board.
“To be very clear, Ariad is not for sale,” said Maria Kantor, the company’s vice president for corporate affairs, in a telephone interview Wednesday afternoon. “We are committed to remaining independent and building a global commercial oncology company. Our business is built around our internally discovered and developed cancer medicines.”
http://www.bizjournals.com/boston/blog/techflash/2013/02/ariad-commits-to-independence-despite.html
"We had a little set back, but we will be stronger than ever in 2014. The best is yet to come," said dr_harvey_berger.
IIIVerson is a TA expert. He is a very honest guy.
III is a very smart guy. I don't think he is shorting. Instead, He may want to buy in case the price goes lower.????
Some others are with us, too.
Thank you, kiki27.
ARIAD strength attributed to inclusion on EMA meeting agenda
http://www.ema.europa.eu/docs/en_GB/document_library/Agenda/2013/12/WC500158398.pdf
The European Medicines Agency will review Ariad's Iclusig at its December meeting, according to a meeting agenda posted to the regulator's website. Ariad shares are up 9.8% to $4.24 following circulation of the agenda.
http://finance.yahoo.com/news/ariad-strength-attributed-inclusion-ema-161303306.html
Iclusig (EMEA/H/C/002695/A-20/0003), Orphan (Ponatinib Hydrochloride), ARIAD Pharma Ltd.
16 December 2013
EMA/CHMP/723655/2013 Rev.3
http://www.ema.europa.eu/docs/en_GB/document_library/Agenda/2013/12/WC500158398.pdf
... a sharp move could put the 3.5's or 4.5's in play.
Unlike some of the so-called Ariad longs, I did not cry about the taken-down flash crash. I did not lose my confidence on the gold bags of ARIA shares even at the darkest time.
One should not put any of his money in the stock market if he could not afford to lose it.
I have a list of other stocks. For examples, I bought SINA at $2 and BIDU at $6. I have been holding a big list of mutual funds for 18 years. So the shorts don't need to be concerned about my life savings. Thank you very much anyway.
Buy and hold the gold bags of ARIA shares. You won't regret if you are a long term investor. To outboard_quack and ryan.brummitt:
I buy the gold bags of ARIA shares at low and sell at high. How could I lose money?
I posted the following in March, 2012. It has been repeatedly posted since then.
--------
"In 2011, I bought ARIA at $11.7, $8.5 and $7.7 on its way dropping from $13.5 to $7.6 while the weak hands were jumping off the train and I was calling for “Ride it Out!”
.
I wrote covered calls early 2012 against the shares bought in 08/2011 (unfortunately, ARIA was higher than the $15 strike price on the expiration day and I lost the shares though I made a handsome profit)."
--------
I bought at $11.7, $8.5 and $7.7 and sold at $15 excluding the premium from the covered call. Did I make money or lose money?
I will hold my ARIA shares bought at $0.625 in Oct. 1999, at $0.81 in Dec. 2008 and at $1.75-2.2 in 2009 until they reaches $48.50. Even at $48.50, I will sell only half of my gold bags of ARIA shares.
Buy and hold the gold bags of ARIA shares. You won't regret if you are a long term investor.
Taking the advantage of tax loss selling time, I bought at $0.81 five years ago.
???
Dew, please teach us about standard formats for reporting SAEs. Is a standard format more crucial than standard criteria? If so, why did the doctors report SAEs per standard criteria without mentioning any standard formats? Are the clinical trial doctors patently silly?
Standard criteria for adverse events is not the same thing as a standard format for reporting them.
... contact Jason Kantor at Credit Swisse'. Their fund is livid over the "mixed" reporting of FDA on Iclusig. Serious issues have been put forth as to why this occurred.
The FDA needs to be "outed" for this bias so damaging to so many. Only winners here have been the insiders where ever they are, i.e., FDA and/or hedgies. Do the math;..140 MILLION share traded(shorted) at a profit ...
"I really appreciate all the information on the event rates for Iclusig, but there just seems to be a pattern where FDA says one thing and then you guys come on the call publicly and say something else. So I'm just wondering, what's the logic of having this debate in a public forum? It just seems like every time you guys do that, they come down hard on you at the next possible opportunity. So I'm just wondering why you think this should be prosecuted in public rather than just in meetings with FDA?", asked Crédit Suisse analyst Jason Kantor at 3Q CC.
Will br vote HB for the greatest CEO of all time, or will he continue dancing on the ceiling in hell?
If Harvey Berger's legal team acts against the FDA, I will vote him for the greatest CEO of all time.AP26113 - Solving the Treatment Resistance Riddle, www.curetoday.com article, Dec. 8, 2013
Andy Bonnett has been dealing with drug-resistant lung cancer since 2008, but has benefited from clinical trials studying new therapies.
Bonnett has had to deal with further shifts in his cancer makeup and treatment. Last summer, his tumors began showing signs of resistance to Xalkori. He started to feel a return of the pain that marked his original disease. After returning from a kayaking trip for people with cancer, Bonnett underwent new scans, which revealed multiple lesions.
He was eligible, however, for a second clinical trial, one with a new agent, still unnamed, called AP26113, which also targets ALK in a different way. AP26113 seems to be able to make it through the blood-brain barrier, and today, Bonnett’s brain metastases are inactive.
"There are many ways of reporting the safety data from a dataset that includes clinical trials with multiple observation points as well as the experience of commercial patients," said DewDiligence
The FDA has the authority to have the safety data reported the way it wants in order to justify its action. This is probably what in DewDiligence's mind. DewDiligence supports the FDA's action, doesn't he? So does Novartis and the other poster who always speaks for Novartis.
Has DewDiligence been ever positive on Ariad?
Standard criteria per which docs report SAEs is not the same thing as stand nonsense per which the FDA reported Iclusig SAEs. You are right.
Standard criteria for adverse events is not the same thing as a standard format for reporting them.
Michael J. Mauro, MD, Leader of the Myeloproliferative Diseases Program at Memorial Sloan-Kettering Cancer Center who was an investigator on both the drug’s Phase I and II trials, said that the different interpretation and calculation of rates of toxicity as reported by the manufacturer versus the FDA was concerning, given that everyone was looking at the same raw data. This is an example of the need for common parameters for calculating such risks, he said. “One can render different opinions on their impact and their weight, but there shouldn’t be different ways of interpreting the risks or different ways of categorizing them. That’s a lesson this experience has taught us.”
http://journals.lww.com/oncology-times/blog/onlinefirst/pages/post.aspx?PostID=902
When one analyst questioned the wisdom of publicly taking issue with US regulators, Ariad chief scientific officer Timothy P. Clackson said, “We felt obligated to, in a very careful way, explain our understanding” of the clinical data because of fears the FDA “created a lot of confusion and questions” among doctors and patients.
"SAE = AE reported as serious by the investigator, per standard criteria"
http://t.co/MP4P3hn3FM
There are certain standard criteria per which the clinical trial doctors report SAEs as evidenced by an ASH presentation titled "... ... 2-Year Follow-up of the PACE Trial"., in which each SAE-reporting slide is labeled with "per standard criteria".
http://t.co/MP4P3hn3FM
If there are no such standard criteria, what are the doctors taking about? Are they lying? Have I been misled by the doctors?
I incline to believe the doctors. I don't trust jq1234's post based upon which you have made your point.
I think you can get the proof/evidence yourself. Please do me a favor and get it yourself.
Or you can go to the post linked by the following URL:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94977421
I have almost reached my daily limit of 15 posts. So I cannot deal with you any longer today. So I would like to ask you another favor. Can we stop here today? You are welcome to request whatever tomorrow. Thank you very much.
How is the class action lawsuit you have jointed progressing? Do you think the lawsuit will kill Ariad? If so, it will be a better Ariad killer than the Novartis Ariad killer Dew was talking about a while ago.
I understand you are an old timer Ariad believer looking forward to the rising of ARIA's price. Is it my delusion?
I will vote Harvey Berger for the greatest CEO of all time if his legal team takes actions against the FDA.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94970959
I agree with Clackson. Ariad is obligated to stay with the standard.
When standard criteria get violated, a lot of confusion and questions arise, which are real, not my delusion.
When one analyst questioned the wisdom of publicly taking issue with US regulators, Ariad chief scientific officer Timothy P. Clackson said, “We felt obligated to, in a very careful way, explain our understanding” of the clinical data because of fears the FDA “created a lot of confusion and questions” among doctors and patients
Why do you think 2a's post I quoted is rubbish? What about your posts? Rubbish or treasure?
What do you think about my recent post:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94970959
Doctors know more about Iclusig than the FDA, I believe patently silily. They report SAEs per standard criteria. The FDA knows more about the standard than the doctors. If the FDA violates the standard, it must be intentional with an agenda.
The clinical trial doctors have treated and examined the patients physically. Don't they know about the safety/toxicity of Iclusig more than anybody else?
Patently silly or not, I firmly believe Doctors know more about Iclusig than the FDA, for a large number of doctors have concluded that "Ponatinib is well tolerated and Adverse Events are manageable". They are a great deal more than any individual doctor, no matter how renowned or how malicious to Ariad an individual may be.
I have to admit that I am patently silly as pointed out by the wise individual who is malicious to Ariad. However, this individual is no less patently silly than me. This bright person even cannot count. The wise man failed to count how many doctors had contributed to the ASH presentations. His wisdom patently sillily beleved that it was an individual's presentation.
I would not believe the conspiracy theory at all if someone who is malicious to Ariad and always speaks for Novartis did not attack the conspiracy theory constantly.